MEK-inhibitor treatment reduces the induction of regulatory T cells in mice after influenza A virus infection.
Animals
T-Lymphocytes, Regulatory
/ immunology
Orthomyxoviridae Infections
/ immunology
Mice
Influenza A virus
/ immunology
Protein Kinase Inhibitors
/ pharmacology
Female
Mice, Inbred C57BL
Forkhead Transcription Factors
/ metabolism
CD8-Positive T-Lymphocytes
/ immunology
Viral Load
/ drug effects
Disease Models, Animal
MEK-inhibitor
Treg - regulatory T cell
immunomodulation
influenza A virus
treatment strategy
zapnometinib
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
23
12
2023
accepted:
10
06
2024
medline:
9
7
2024
pubmed:
9
7
2024
entrez:
9
7
2024
Statut:
epublish
Résumé
Regulatory T cells (Tregs) play a crucial and complex role in balancing the immune response to viral infection. Primarily, they serve to regulate the immune response by limiting the expression of proinflammatory cytokines, reducing inflammation in infected tissue, and limiting virus-specific T cell responses. But excessive activity of Tregs can also be detrimental and hinder the ability to effectively clear viral infection, leading to prolonged disease and potential worsening of disease severity. Not much is known about the impact of Tregs during severe influenza. In the present study, we show that CD4
Identifiants
pubmed: 38979428
doi: 10.3389/fimmu.2024.1360698
pmc: PMC11228811
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Forkhead Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1360698Informations de copyright
Copyright © 2024 Koch-Heier, Vogel, Füll, Ebensperger, Schönsiegel, Zinser and Planz.
Déclaration de conflit d'intérêts
OP is consultant for Atriva Therapeutics GmbH. JK-H, YF, ME, and AS were employees of Atriva Therapeutics GmbH. AV is employee of and has securities from BioNTech SE. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Atriva Therapeutics GmbH (Tuebingen, Germany), licensee of zapnometinib. The funder had the following involvement with the study: study design, data, and decision to publish.